Beyond Primary HER2 Expression: Trastuzumab Deruxtecan’s Efficacy in Brain Metastasis

Glori Das; Stephen T.C. Wong; Hong Zhao

doi:10.3390/cancers16203525

Beyond Primary HER2 Expression: Trastuzumab Deruxtecan’s Efficacy in Brain Metastasis

Glori Das, Stephen T.C. Wong, Hong Zhao

Research output: Contribution to journal › Editorial › peer-review

3 Scopus citations

Abstract

This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.

Original language	English (US)
Article number	3525
Journal	Cancers
Volume	16
Issue number	20
DOIs	https://doi.org/10.3390/cancers16203525
State	Published - Oct 2024

ASJC Scopus subject areas

Oncology
Cancer Research

Divisions

Medical Oncology

Access to Document

10.3390/cancers16203525

Cite this

@article{ebb0c558042d4b5f9d25c66c5913efb4,

title = "Beyond Primary HER2 Expression: Trastuzumab Deruxtecan{\textquoteright}s Efficacy in Brain Metastasis",

abstract = "This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.",

author = "Glori Das and Wong, \{Stephen T.C.\} and Hong Zhao",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = oct,

doi = "10.3390/cancers16203525",

language = "English (US)",

volume = "16",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "20",

}

TY - JOUR

T1 - Beyond Primary HER2 Expression

T2 - Trastuzumab Deruxtecan’s Efficacy in Brain Metastasis

AU - Das, Glori

AU - Wong, Stephen T.C.

AU - Zhao, Hong

PY - 2024/10

Y1 - 2024/10

N2 - This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.

AB - This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.

UR - https://www.scopus.com/pages/publications/85207675128

UR - https://www.scopus.com/inward/citedby.url?scp=85207675128&partnerID=8YFLogxK

U2 - 10.3390/cancers16203525

DO - 10.3390/cancers16203525

M3 - Editorial

AN - SCOPUS:85207675128

SN - 2072-6694

VL - 16

JO - Cancers

JF - Cancers

IS - 20

M1 - 3525

ER -

Beyond Primary HER2 Expression: Trastuzumab Deruxtecan’s Efficacy in Brain Metastasis

Abstract

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this